Loading clinical trials...

Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia | Clinical Trials | Clareo Health

COMPLETEDNA

Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia

Cognitive Stimulation in Activities of Daily Living for Individuals Living With Mild-to-Moderate Dementia (CS-ADL): a Pilot Randomised Controlled Trial

NCT06147479•National University of Ireland, Galway, Ireland

View on ClinicalTrials.gov

Summary

The goal of this study is to test the effect of CS-ADL is on people living with early to middle stage dementia. The study also aims to evaluate the feasibility of conducting larger-scale research of CS-ADL. The main questions it aims to answer are: * What is the effect of CS-ADL on the ability of people with early to middle stage dementia to carry out their everyday activities? * What is the effect of CS-ADL on the memory, mood, communication, and quality of life of people living with early to middle stage dementia? What is the feasibility of conducting large-scale research of CS-ADL? Participants will take part in a group program that lasts 7 weeks, with one session per week, lasting two hours. Participants will take part in rewarding and stimulating activities, for example discussion, reminiscence, music, and practical activities such as baking, cooking, gardening. Participants will be asked to complete a variety of questionnaires before and after taking part in the group. Researchers will compare a group receiving CS-ADL to a group receiving their usual care, to explore whether CS-ADL works well in comparison to typical treatment provided by the health services.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants must have a formal diagnosis of major neurocognitive disorder (dementia) as per the DSM-V criteria.
•Participants must have a mild-to-moderate cognitive impairment as classified by the Montreal Cognitive Assessment (MoCA).
•Participants must have some ability to communicate and understand communication, determined by a score of 1 or 0 on questions 12 and 13 of the Clifton Assessment Procedures for the Elderly-Behaviour Rating Scale.
•Participants must be able to see and hear well enough to participate in the group.

Exclusion Criteria

•Individuals with severe dementia, i.e., an MMSE\<10, will be excluded as most CS interventions are not applicable for those with severe cognitive impairment.
•Participants will be excluded if they have significant uncontrolled disruptive behaviours.
•Premorbid diagnosis of a learning disability.
•A significant physical illness/disability that may affect participation during intervention sessions or assessments.

Locations (1)

University of Galway

Galway, Connacht, Ireland

Key Dates

Start Date

November 3, 2023

Primary Completion Date

June 21, 2024

Completion Date

June 21, 2024

Last Updated

August 6, 2024

Enrollment

ACTUAL participants

Conditions

DementiaDementia, MildDementia Moderate

Interventions

CS-ADL (Cognitive stimulation in Activities of Daily Living)

BEHAVIORAL

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGPHASE3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Testing the Pain Clinical Practice Guideline

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Circadian Rhythm and Other Factors in Memory Clinic Patients

Neurocognitive Assessment Platform 4 Alzheimer